furosemide + hypertonic saline solution

Furosemide + hypertonic saline solution is a combination therapy consisting of the loop diuretic furosemide and intravenous hypertonic saline (typically 2.6% to 3.4% sodium chloride). This regimen is used primarily in patients with acute decompensated heart failure or refractory congestive heart failure who are resistant to standard diuretic therapy. Furosemide acts by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, promoting natriuresis and diuresis. Hypertonic saline augments this effect by increasing intravascular volume, correcting hypochloremia, and improving renal perfusion, which can overcome diuretic resistance and enhance urine output. The combination has been shown in multiple randomized controlled trials and meta-analyses to increase urine output, reduce hospital stay duration, improve weight loss, correct electrolyte imbalances (notably hyponatremia), lower serum creatinine levels, and improve neurohormonal markers compared to furosemide alone[1][6][7]. It is not a branded product but rather an off-label therapeutic strategy used in specialized settings.

Other names

HSS + furosemidehypertonic saline solution + furosemidefurosemide + hypertonic saline